FDA names controlled substance staff director
Executive Summary
Michael Klein will permanently replace Deborah Leiderman as director of CDER's Controlled Substance Staff. Following Leiderman's exit May 31, Klein was named acting director, and before that, was the team leader and associate director to the staff. Klein has been with CDER for 19 years in a number of offices and previously served as a senior scientist with the DEA
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.